Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia.

CNS Spectr 2017 10 9;22(5):415-426. Epub 2017 Feb 9.

10The Zucker Hillside Hospital,Psychiatry Research,Northwell Health,Glen Oaks,New York,USA.

Objective: Our aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia.

Methods: We conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI 95%) were calculated.

Results: Six RCTs were eligible (minocycline n=215, placebo n=198) that demonstrated minocycline's superiority versus placebo for reducing endpoint Positive and Negative Syndrome Scale (PANSS) total scores (SMD=-0.59; CI 95%=[1.15, -0.03]; p=0.04), negative (SMD=-0.76; CI 95%=[-1.21, -0.31]; p=0.001); general subscale scores (SMD=-0.44; CI 95%=[-0.88, -0.00]; p=0.05), Clinical Global Impressions scores (SMD=-0.50; CI 95%=[-0.78, -0.22]; p<0.001); and executive functioning (SMD=0.22; CI 95%=[0.01, 0.44]; p=0.04). Endpoint PANSS positive symptom scores (p=0.13), depression rating scale scores (p=0.43), attention (p=0.47), memory (p=0.52), and motor speed processing (p=0.50) did not significantly differ from placebo, before execution of a trim-and-fill procedure. Minocycline did not differ compared to placebo on all-cause discontinuation (p=0.56), discontinuation due to inefficacy (p=0.99), and intolerability (p=0.51), and due to death (p=0.32). Data from one open-label study (N=22) and three case series (N=6) were consistent with the metaanalytic results.

Conclusions: Minocycline appears to be an effective adjunctive treatment option in schizophrenia, improving multiple relevant disease dimensions. Moreover, minocycline has an acceptable safety and tolerability profile. However, more methodologically sound and larger RCTs remain necessary to confirm and extend these results.

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852916000638DOI Listing
October 2017
29 Reads

Publication Analysis

Top Keywords

meta-analysis efficacy
8
efficacy safety
8
review meta-analysis
8
systematic review
8
positive negative
8
n=198 demonstrated
4
depressive cognitive
4
-031] p=0001
4
95%=[-121 -031]
4
negative depressive
4
symptom rating
4
rating scales
4
placebo n=198
4
smd=-076 95%=[-121
4
meta-analysis positive
4
scale panss
4
cognitive symptom
4
endpoint positive
4
case reports/series
4
reports/series evaluating
4

References

(Supplied by CrossRef)
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Kelly et al.
J Clin Psychopharmacol 2015

Similar Publications